Gilman Hill Asset Management LLC Buys 476 Shares of Abbott Laboratories $ABT

Gilman Hill Asset Management LLC boosted its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 10,004 shares of the healthcare product maker’s stock after purchasing an additional 476 shares during the period. Gilman Hill Asset Management LLC’s holdings in Abbott Laboratories were worth $1,361,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in ABT. Hughes Financial Services LLC bought a new position in Abbott Laboratories during the first quarter valued at about $27,000. Abound Financial LLC bought a new position in Abbott Laboratories during the first quarter valued at about $28,000. Elequin Capital LP purchased a new position in shares of Abbott Laboratories in the first quarter worth about $30,000. Wormser Freres Gestion purchased a new position in shares of Abbott Laboratories in the fourth quarter worth about $32,000. Finally, JCIC Asset Management Inc. purchased a new position in shares of Abbott Laboratories in the first quarter worth about $32,000. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ABT. Morgan Stanley lifted their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Wells Fargo & Company reduced their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research note on Friday, July 18th. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Mizuho lifted their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Finally, Leerink Partners began coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a “market perform” rating and a $143.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $144.47.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Up 1.1%

ABT stock opened at $132.76 on Wednesday. The company has a market capitalization of $231.06 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 2.49 and a beta of 0.69. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The company’s 50 day moving average price is $130.35 and its two-hundred day moving average price is $131.22. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the firm posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.